

Rethinking Fabry disease

Facing challenges in diagnosis and renal disease control

Fabry is a rare, chronic, progressive disease with multisystemic involvement¹⁻⁴ that can lead to significant renal decline and terminal renal failure.³ Patients can receive clinical benefit from current therapies, but **disease progression commonly continues to impact the day-to-day quality of life of Fabry patients**—even with standard-of-care management.⁵

It's critical to take a holistic view of the impact of Fabry disease—considering not only the nephrological implications, but also the daily issues and long-term challenges that individual patients may face.

Revealing unmet needs in Fabry disease

The standard of care in Fabry disease hasn't changed for nearly 20 years.⁶⁻¹⁰ Current therapies can provide clinical benefit, but significant diagnostic and management challenges remain.^{5,6,8-13}

Because of the spectrum of potential manifestations of Fabry disease, patients and physicians continue to encounter unmet needs:



Time to diagnosis:

may be 30 years

or more⁶



Limited treatment options^{5,8,10}



Administration challenges¹³



Delayed treatment initiation^{6,12}



Continuing daily symptoms despite treatment⁵

Regardless of current management, Fabry disease may eventually progress to severe clinical manifestations—including terminal renal failure.^{1,9}

The progressive dangers of renal involvement in Fabry

Patients with Fabry disease may exhibit diverse forms of renal histopathology. Fabry affects all cell types within the kidney, even if patients have minimal proteinuria and a normal estimated glomerular filtration rate (eGFR).¹⁴ Nephrologists will often be able to recognize early and relevant signs of renal disease, thereby helping to ensure early diagnosis and appropriate management, with an optimal clinical outcome for the patient.^{3,11,15}

Proteinuria—a telltale sign of renal decline in Fabry

Proteinuria is typically the earliest sign of renal involvement in Fabry disease, found in 10% of pediatric patients—and occurring as young as 2 years of age. By age 35, proteinuria is present in approximately 50% of patients, reinforcing that early intervention is critical in slowing the progression of disease in Fabry.¹¹



Proteinuria progression in Fabry disease¹¹

eGFR decline and progression to renal failure


Another clinical manifestation of Fabry is decreasing eGFR, progressing to kidney failure over time. This often necessitates clinical intervention by the third or fourth decade of a patient's life. In one trial that assessed the decrease in eGFR, patients who were treated with ERT and whose severity of disease required clinical intervention initiated renal replacement therapy between 33 and 47 years of age.³

Symptomatic renal complications typically emerge early, in young adulthood. These include chronic kidney disease progression to kidney failure. In fact, according to a review article, **in patients who were not treated with ERT, the mean age at which patients generally reach kidney failure from Fabry disease is 40 years.**¹⁵



The hidden impact of Fabry disease—renal involvement and beyond

Even with current, standard-of-care management, patients may still experience a variety of day-to-day symptoms of their disease, particularly pain of differing forms and severity. Patients may even adjust their lives around such symptoms as their disease, including its renal complications, continues to progress.⁵



An expert look at existing needs in Fabry disease

Hear from leading nephrologist Dr. Eric Wallace and a panel of healthcare experts as they discuss how far we've come in treating Fabry disease—and what's left to be done



Staying vigilant about the renal warning signs of Fabry disease

Early diagnosis is key

Patients with Fabry often have long delays in their diagnosis and consequent initiation of treatment sometimes 30 years or more. By the third or fourth decade of life, many patients may already exhibit proteinuria or even reach terminal renal failure.^{3,11,15}

Early intervention to maximize clinical benefit¹⁵


Even with standard-of-care management, Fabry disease may eventually progress to severe clinical manifestations.^{1,9} The best way to prevent or slow this progression is by initiating treatment as early as possible.¹⁵

Awareness and action can create better possibilities for people with Fabry disease.

Keeping these strategies top-of-mind in your practice will optimize care for your patients.



Ongoing and proactive disease management, including elevating the importance of patient–





Recognition of limitations of current therapies, from quality of life to disease progression



Shortening the time to diagnosis



An eye on the horizon for other strategies

By rethinking our plan today, we may be able to change outcomes tomorrow.

GET INVOLVED

References: 1. Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MGW, Hollak CEM. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. *Orphanet J Rare Dis*. 2013;8:47. doi:10.1186/1750-1172-6-47. 2. Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MGW, Hollak CEM. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. *J Inherit Metab Dis*. 2014;37(3):341-352. doi:10.1007/ s10545-014-9677-8. 3. Weidemann F, Niemann M, Störk S, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. *J Intern Med*. 2013;274(4):331-341. doi:10.1111/joim.12077. 4. Desnick RJ, Brady R, Barranger J, et al. Fabry disease: an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. *Ann Intern Med*. 2003;38(4):338-346. doi:10.07326/0003-4819-138-4-2.00302180(4):338-346. doi:10.1073/gl(10):2866-2880.
00014. 5. Morand O, Johnson J, Walter J, et al. Symptoms and quality of life in patients with Fabry disease: results from an international patient survey. *Adv Ther*. 2019;36(10):2866-2880.
00161. 4. 5. Morand D, Johnson J, Walter J, et al. Symptoms and quality of life in patients with Fabry disease. *Cochrane Database Syst Rev*. 2016;7(7):CD006663. doi:10.1011/j.jcin.12914. **7.** Brady M, Montgomery E, Brennan P, Mohindra R, Sayer JA. Diagnosing Fabry disease—delays and difficulties within discordant siblings. *QIJJ*. 2016;128(5):590. doi:10.1002/j.jci.2914. **7.** Brady M, Montgomery E, Brennan P, Mohindra R, Sayer JD. Eagnosing Fabry disease-moth setup, rainger H, Pagon RA, et al., eds. *GeneReviews*¹, University of Washington, Seattle; 1993-2020. Accessed August 12, 2020. https://www.ncbi.nlm.nih.gov/books/NBK1292/10. Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone mi

